Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 4:4:64.
doi: 10.3389/fendo.2013.00064. eCollection 2013.

Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement

Affiliations

Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement

Mary L Reed et al. Front Endocrinol (Lausanne). .

Abstract

Deficiency of growth hormone (GH) in adults results in a syndrome characterized by decreased muscle mass and exercise capacity, increased visceral fat, impaired quality of life, unfavorable alterations in lipid profile and markers of cardiovascular risk, decrease in bone mass and integrity, and increased mortality. When dosed appropriately, GH replacement therapy (GHRT) is well tolerated, with a low incidence of side effects, and improves most of the alterations observed in GH deficiency (GHD); beneficial effects on mortality, cardiovascular events, and fracture rates, however, remain to be conclusively demonstrated. The potential of GH to act as a mitogen has resulted in concern over the possibility of increased de novo tumors or recurrence of pre-existing malignancies in individuals treated with GH. Though studies of adults who received GHRT in childhood have produced conflicting reports in this regard, long-term surveillance of adult GHRT has not demonstrated increased cancer risk or mortality.

Keywords: IGF-I; adult growth hormone deficiency; growth hormone; growth hormone risks; growth hormone treatment; insulin-like growth factor-I.

PubMed Disclaimer

References

    1. Abs R., Feldt-Rasmussen U., Mattsson A. F., Monson J. P., Bengtsson B. A., Góth M. I., et al. (2006). Determinants of cardiovascular risk in 2589 hypopituitary GH deficient adults – a KIMS database analysis. Eur. J. Endocrinol. 155, 79–9010.1530/eje.1.02179 - DOI - PubMed
    1. Ahmad A., Hopkins M. T., Thomas J., Ibrahim H., Fraser W. D., Vora J. P., et al. (2001). Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement. Clin. Endocrinol. 54, 709–71710.1046/j.1365-2265.2001.01275.x - DOI - PubMed
    1. Aimaretti G., Corneli G., Razzore P., Bellone S., Baffoni C., Arvat E., Etalname A. (1998). Comparison between insulin induced hypoglycemia and growth hormone (GH) releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J. Clin. Endocrinol. Metab. 83, 1615–161810.1210/jc.83.5.1615 - DOI - PubMed
    1. al-Shoumer K. A., Gray R., Anyaoku V., Hughes C., Beshyah S., Richmond W., et al. (1998). Effects of four years’ treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin. Endocrinol. (Oxf.) 48, 795–80210.1046/j.1365-2265.1998.00460.x - DOI - PubMed
    1. Al-Shoumer K. A., Page B., Thomas E., Murphy M., Beshyah S. A., Johnston D. G. (1996). Effects of four years’ treatment with biosynthetic human growth hormone (GH) on body composition in GH-deficient hypopituitary adults. Eur. J. Endocrinol. 135, 559–56710.1530/eje.0.1350559 - DOI - PubMed

LinkOut - more resources